Akums Drugs and Pharmaceuticals Limited (BOM:544222)
India · Delayed Price · Currency is INR 814.70
+14.10 (1.76%)
At close: Oct 6, 2026
BOM:544222 Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 124,725 | 71,361 | 74,479 | - | - | - | |
Market Cap Growth | 82.58% | -4.19% | - | - | - | - |
Enterprise Value | 110,014 | 55,917 | 71,969 | - | - | - |
Last Close Price | 814.70 | 463.86 | 472.37 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 42.75 | 27.96 | 22.02 | - | - | - |
PS Ratio | 2.77 | 1.64 | 1.81 | - | - | - |
PB Ratio | 3.74 | 2.14 | 2.43 | - | - | - |
P/TBV Ratio | 3.77 | 2.16 | 2.45 | - | - | - |
P/FCF Ratio | 13.12 | 7.51 | 38.61 | - | - | - |
P/OCF Ratio | 10.56 | 6.04 | 16.01 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.44 | 1.28 | 1.75 | - | - | - |
EV/EBITDA Ratio | 19.49 | 10.95 | 16.05 | - | - | - |
EV/EBIT Ratio | 26.73 | 15.11 | 23.21 | - | - | - |
EV/FCF Ratio | 11.57 | 5.88 | 37.31 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.05 | 0.79 | 0.86 | 0.64 |
Debt / EBITDA Ratio | 0.34 | 0.37 | 0.32 | 1.17 | 2.07 | 0.98 |
Debt / FCF Ratio | - | 0.20 | 0.77 | 3.03 | - | - |
Net Debt / Equity Ratio | -0.45 | -0.45 | -0.14 | 0.40 | 0.65 | 0.48 |
Net Debt / EBITDA Ratio | -2.69 | -2.92 | -0.94 | 0.61 | 1.63 | 0.74 |
Net Debt / FCF Ratio | - | -1.57 | -2.18 | 1.54 | -3.11 | -1.32 |
Asset Turnover | - | 0.91 | 1.08 | 1.23 | 1.15 | 1.40 |
Inventory Turnover | - | 3.61 | 3.81 | 3.85 | 3.24 | 4.19 |
Quick Ratio | - | 2.26 | 1.50 | 0.92 | 0.80 | 0.78 |
Current Ratio | - | 3.25 | 2.55 | 1.60 | 1.52 | 1.49 |
Return on Equity (ROE) | - | 8.02% | 18.17% | 0.11% | 14.51% | -33.18% |
Return on Assets (ROA) | - | 4.84% | 5.08% | 6.62% | 3.74% | 7.54% |
Return on Invested Capital (ROIC) | 15.36% | 11.07% | 16.91% | 32.57% | 11.64% | 34.07% |
Return on Capital Employed (ROCE) | - | 8.50% | 9.60% | 15.60% | 9.50% | 17.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.34% | 3.58% | 4.54% | - | - | - |
FCF Yield | 7.62% | 13.32% | 2.59% | - | - | - |
Dividend Yield | 0.37% | 0.22% | - | - | - | - |
Buyback Yield / Dilution | -0.68% | -2.33% | -4.58% | - | - | - |
Total Shareholder Return | -0.31% | -2.12% | -4.58% | - | - | - |